Trial Design
This is a prospective, randomized, double-blind, controlled, and
noninferiority trial implemented in
First Affiliated Hospital, University of Science and Technology of China
(USTC) (Approval No. of the ethics committee: 20171219), and the trial
was registered in the Chinese Clinical Trial Registry
(ChiCTR2100053517). The trial compliance with ethics guidelines. From
November 2021 to March 2022, 88 patients were recruited. Patients were
given a detailed explanation of the study protocol and informed of the
potential benefits and side effects of the technology’s development.
Informed consent was obtained from the patient or family. Figure 1 shows
the flow diagram of participant recruitment.